AMY BROWN: Open Payments
NPI 1558818401 · FRENCHBURG, KY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$598 in 32 payments from 15 companies in 2025. Trend: 2023 $692 · 2024 $679 · 2025 $598
Food & beverage: $598
| Company | Payments | Amount |
|---|---|---|
| GlaxoSmithKline, LLC. | 5 | $92 |
| Amgen Inc. | 4 | $83 |
| Indivior Inc. | 4 | $79 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $60 |
| Abbott Laboratories | 2 | $40 |
| Novartis Pharmaceuticals Corporation | 2 | $37 |
| AstraZeneca Pharmaceuticals LP | 2 | $36 |
| Bayer Healthcare Pharmaceuticals Inc. | 2 | $34 |
| Exact Sciences Corporation | 2 | $33 |
| Boston Scientific Corporation | 1 | $28 |
Products named: TRELEGY ELLIPTA, SUBLOCADE, OTEZLA, CAPLYTA, FREESTYLE LIBRE 3, LEQVIO, BREZTRI, Kerendia.
Industry payments across KY — which companies pay providers there.
